Mestag Therapeutics, a biotech company harnessing new insights into fibroblast-immune interactions, has entered into a license and collaboration agreement with Merck & Co. to identify novel targets for the development of therapies against inflammatory diseases.    Mestag will employ its Reversing Activated Fibroblast Technology (RAFT) platform purposely built to model the pathogenic role of fibroblasts in human disease, to identify novel drug targets. Merck has the option to license one or...